Study on the Mechanisms of Banxia Xiexin Decoction in Treating Diabetic Gastroparesis Based on Network Pharmacology

• Published in: Interdisciplinary sciences : computational life sciences Vol. 12; no. 4; pp. 487 - 498
• Main Authors: Wu, Tingchao, Yue, Rensong, Li, Liang, He, Mingmin
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2020; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Cbfa-1 protein; Chemical compounds; Computational Biology/Bioinformatics; Computational Science and Engineering; Computer Appl. in Life Sciences; CXCL10 protein; CXCL11 protein; Diabetes; Diabetes mellitus; Dopamine D1 receptors; Dopamine D2 receptors; Gelatinase B; Health Sciences; Ingredients; Intercellular adhesion molecule 1; Interleukin 17; Interleukin 6; Kaempferol; Life Sciences; Mathematical and Computational Physics; Mcl-1 protein; Medicine; Molecular modelling; Monocyte chemoattractant protein 1; Myc protein; Original Research Article; Pharmacology; Quercetin; Signal transduction; Signaling; Statistics for Life Sciences; Theoretical; Theoretical and Computational Chemistry; Diabetic gastroparesis; Network pharmacology; Banxia Xiexin decoction; Traditional Chinese Medicine
• ISSN: 1913-2751; 1867-1462
• DOI: 10.1007/s12539-020-00389-1

In China, Banxia Xiexin decoction (BXD) is applied to treat diabetic gastroparesis (DGP), but its key active ingredients and mechanisms against DGP are unclear. This study is designated to reveal the molecular mechanisms of BXD in treating DGP by adopting a creative approach known as network pharmacology to explore the active ingredients and therapeutic targets of BXD. In our study, 730 differentially expressed genes of DGP were obtained, and 30 potential targets of BXD against DGP were screened out (including ADRB2, DRD1, FOS, MMP9, FOSL1, FOSL2, JUN, MAP2, DRD2, MYC, F3, CDKN1A, IL6, NFKBIA, ICAM1, CCL2, SELE, DUOX2, MGAM, THBD, SERPINE1, ALOX5, CXCL11, CXCL2, CXCL10, RUNX2, CD40LG, C1QB, MCL1, and ADCYAP1). Based on the findings, BXD contains 60 compounds with therapeutic effect on DGP, including the key active ingredients such as quercetin, wogonin, baicalein, beta-sitosterol, and kaempferol. Sixty-eight pathways including TNF signaling pathway, IL-17 signaling pathway, and AGE-RAGE signaling pathway were significantly enriched. In this study, the mechanisms of BXD in treating DGP are affirmed to be a complex network with multi-target and multi-pathway, which provides a reference for future experimental studies.